Asian Stocks Gain Amid Iran Conflict Uncertainty 
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
Explosion and Fire Erupt at Valero Oil Refinery in Port Arthur, Texas 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
Asian Currencies Stay Muted as Dollar Holds Firm Amid Iran Uncertainty 
FDA Biologics Chief Vinay Prasad to Leave Agency in April Amid Policy Disputes 
U.S. Oil Prices Slide as Middle East Ceasefire Talks Spark Market Optimism 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
WTO Reform Talks Begin in Cameroon Amid Global Trade Tensions 
Bank of Japan Officials Signal Continued Interest Rate Hikes Amid Inflation Concerns 
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
South Korean pharmaceutical and biotech companies are collaborating to develop new drugs using artificial intelligence (AI).
AI can predict whether a chemical compound is suitable for human use, thereby speeding up the identification of potential substances and enabling the selection of appropriate clinical patients.
There are over 100 cases where candidate substances for new drugs are under development using AI, with over 50 percent carried out through collaborations between domestic and foreign companies, according to the Korea Pharmaceutical and Bio-pharma Manufacturers Association.
HK inno.N Corp. and AinB recently signed an MOU to identify a new antibody candidate substance for cell and gene therapies and establish an antigen design platform for vaccine development.
Last year, Pharos iBio inked a deal with Yuhan Corp. to promote the joint study and technology transfer of the AI-based KRAS inhibitor.
This company is now carrying out a phase 1 clinical trial in Korea and Australia after developing PHI-101, a candidate substance for the treatment of leukemia, using its AI platform, Chemiverse.
Moreover, Oncocross, which has AI technology to identify the optimal disease for drugs, signed a joint study and development contract with Boryung Corp. in February to expand the indications of hypertension treatment.
